| Identification | Back Directory | [Name]
Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- | [CAS]
1293289-69-6 | [Synonyms]
TRC160334
Glycine, N-[(7,8,9,10-tetrahydro-2-hydroxy-4-oxo-4H,6H-cyclohepta[4,5]thiazolo[3,2-a]pyrimidin-3-yl)carbonyl]- | [Molecular Formula]
C14H15N3O5S | [MOL File]
1293289-69-6.mol | [Molecular Weight]
337.35 |
| Chemical Properties | Back Directory | [density ]
1.74±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (148.21 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
3.58±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury[1]. | [in vivo]
TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen[1].
TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis[1].
TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control[1]. | Animal Model: | Sprague-Dawley male rats (250–300 g)[1] | | Dosage: | 0.1 and 0.3 mg/kg | | Administration: | I.p. | | Result: | Significantly reduced serum creatinine and blood urea nitrogen.
|
| Animal Model: | Sprague-Dawley male rats (250–300 g)[1] | | Dosage: | 0.3 and 0.6 mg/kg | | Administration: | I.p. | | Result: | Showed reducing trends for acute tubular necrosis.
|
| [References]
[1] Jamadarkhana P, et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol. 2012;36(3):208-218. DOI:10.1159/000341870 |
|
|